Tufts Center for the Study of Drug Development, Tufts University School of Medicine, 145 Harrison Avenue, Boston, MA, 02111, USA.
AbbVie, Lake Bluff, IL, USA.
Ther Innov Regul Sci. 2022 Sep;56(5):777-784. doi: 10.1007/s43441-022-00418-9. Epub 2022 Jun 10.
There is little to no empirical data on the race and ethnicity of the global community of professionals conducting clinical trials funded by pharmaceutical and biotechnology companies and little empirical evidence on the relationship between the race and ethnicity of investigative site personnel and the overall and corresponding diversity of participants enrolled.
A global online survey conducted in mid-2021 gathered responses from 3462 clinical research professionals representing approximately 3300 distinct investigative sites.
Worldwide, including all research settings, the majority (64%) of investigative site personnel are White, 20% are LatinX, 6% are Black, 7% are Asian and 3% are other races and ethnicities (e.g., indigenous peoples, Pacific Islander, Middle Eastern, etc.). The representation of non-white site personnel is significantly higher in North America and Rest of World (ROW) compared to Europe. The highest levels of personnel diversity are found in private community-based practices, investigative sites and site networks. A significant correlation (p < 0.001) was found between site personnel diversity and patient enrollment diversity worldwide. As the mix of site personnel by race and ethnicity increases, the diversity of patients enrolled-except for Asian patients in sites outside of North America-also increases. A significant relationship was also found between the proportion of a given race or ethnicity of investigative site personnel and the corresponding race and ethnicity of patients enrolled.
An opportunity exists to address under-representation in clinical trials through identifying, hiring and supporting investigative site personnel to best reflect the patient communities that they serve.
几乎没有关于在制药和生物技术公司资助的临床试验中开展工作的全球专业人士的种族和民族的经验数据,也几乎没有关于研究现场人员的种族和民族与入组参与者的总体和相应多样性之间的关系的经验证据。
2021 年年中进行的一项全球在线调查从 3462 名代表大约 3300 个不同研究现场的临床研究专业人员那里收集了回复。
在全球范围内,包括所有研究环境中,大多数(64%)研究现场人员为白人,20%为拉丁裔,6%为黑人,7%为亚洲人,3%为其他种族和民族(例如,土著人民、太平洋岛民、中东等)。与欧洲相比,北美和世界其他地区(ROW)的非白人现场人员的代表性明显更高。在私人社区为基础的实践、研究现场和现场网络中,人员多样性最高。在全球范围内,发现现场人员多样性与患者入组多样性之间存在显著相关性(p<0.001)。随着现场人员的种族和民族构成的多样性增加,入组患者的多样性也会增加——除了北美以外的地区的研究现场中的亚洲患者。还发现研究现场人员的特定种族或民族比例与入组患者的相应种族和民族之间存在显著关系。
通过确定、雇用和支持研究现场人员,使其最好地反映他们所服务的患者群体,为临床试验中的代表性不足提供了一个机会。